Axinn Successfully Represents Alvogen Before FTC
November 3, 2015
Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen’s approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan’s bid for Perrigo is valued at $25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC’s Mylan press release can be found here.
The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
American Bar Association 2025 Asia-Pacific Conference
Speaking Engagement
Antitrust
NBA Commercial Law Section 38th Annual Corporate Counsel Conference
Sponsorship
Antitrust
GCR Live: Law Leaders Global 2025
Speaking Engagement
Antitrust
The 32nd Annual Marketing Partner Forum
Event
SABA North America Corporate Counsel Retreat 2025
Sponsorship
Antitrust
Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
Client Alerts
Antitrust
Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
Awards & Recognitions
Antitrust
Merger Remedies Back in Vogue Under Trump
Media Mentions
Antitrust
Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation
Axinn Viewpoints
Intellectual Property
A POSA’s Motivation Is Not Required To Be the Same as the Inventor’s in Evaluating Obviousness
Axinn Viewpoints
Intellectual Property